Please assess the completion status of the following clinical trial:

Trial Title: CLARITY Extension Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Randomized in Trial 25643 and satisfied one of the following:~  * Completed randomized treatment course and scheduled visits for the full 96 weeks; or~ * Did not complete the randomized treatment course in Trial 25643 but elected to receive rescue treatment with Rebif®, another beta-interferon, or glatiramer acetate and completed scheduled clinic visits for the full 96 weeks; or~ * Did not complete the randomized treatment course in Trial 25643, declined rescue with Rebif®, another beta-interferon, or glatiramer acetate and still completed scheduled clinic visits for the full 96 weeks; or~ * Did not complete the randomized treatment course in Trial 25643, were not eligible for rescue option with Rebif®, and still completed scheduled clinic visits for the full 96 weeks~* Male or female, between 18 and 65 years of age (inclusive, at time of informed consent for Trial 25643)~* No medical history or evidence of latent tuberculosis infection (LTBI) or tuberculosis (TB), as evidenced by TB skin test or chest X-ray~* All of the following laboratory hematologic parameters evaluated as normal (as define below, inclusively) within 28 days of first dosing of blinded study medication at study Day 1:~  * Hemoglobin = 11.6 to 16.2 gram per deciliter (g/dL)~ * Leukocytes (total white blood cell) = 4.1 to 12.3\*10\^3 per microliter~ * Absolute lymphocyte count (ALC) = 1.02 to 3.36\*10\^3 per microliter~ * Absolute neutrophil count (ANC) = 2.03 to 8.36\*10\^3 per microliter~ * Platelet count = 140 to 450\*10\^3 per microliter~* Other protocol-defined inclusion/exclusion criteria may apply~Exclusion Criteria:~* Participants who were not enrolled in Trial 25643~* Participant has moderate to severe renal impairment~* Use of mitoxantrone, total lymphoid irradiation, myelosuppressive therapy, campath-1h, cyclophosphamide, azathioprine, methotrexate or natalizumab at any time during and since Trial 25643~* Use of cytokine or anti-cytokine therapy, intravenous immunoglobulin (IVIG) or plasmapheresis at any time during and since Trial 25643~* Treatment with oral or systemic corticosteroids or adrenocorticotropic hormone within 28 days before Study Day 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cladribine Low/Placebo (LLPP) (Type: PLACEBO_COMPARATOR): None
- Cladribine High Dose/Placebo (HLPP) (Type: PLACEBO_COMPARATOR): None
- Cladribine Low/Low Dose (LLLL) (Type: EXPERIMENTAL): None
- Cladribine High/Low Dose (HLLL) (Type: EXPERIMENTAL): None
- Placebo/Cladribine Low Dose (PPLL) (Type: EXPERIMENTAL): None
- Placebo/No Treatment (Type: NO_INTERVENTION): None
- Cladribine 3.5 mg/kg/No Treatment (Type: NO_INTERVENTION): Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).
- Cladribine 5.25 mg/kg/No Treatment (Type: NO_INTERVENTION): Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).

Based on this trial design, predict the completion outcome and termination type (if applicable).